The present disclosure provides a method of inducing or promoting darkening of the skin and/or melanogenesis, a method of treating a skin condition or disorder, in particular hypopigmentation, comprising administration of a polycationic aliphatic amine, wherein said polycationic aliphatic amine preferably is putrescine, spermidine and spermine. The invention further includes corresponding methods of reducing or preventing darkening of skin and/or melanogenesis, or related methods of treating a skin condition or disorder, comprising administration of at least an inhibitor of polycationic aliphatic amine transport or synthesis, wherein said inhibitor is preferably trimer44NMe or difluoromethylornithine (DFMO) respectively.

This disclosure provides, inter alia, an optimized strain of Nitrosomonas eutropha (N. eutropha) designated D23, D23-100, or AOB D23-100. N. eutropha bacteria disclosed in this application have desirable properties, e.g., optimized properties, such as the ability to suppress growth of pathogenic bacteria, and an enhanced ability to produce nitric oxide and nitric oxide precursors. The N. eutropha herein may be used, for instance, to treat diseases associated with low nitrite levels, skin diseases, and diseases caused by pathogenic bacteria.

Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.

Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.

A complex formed by a zinc oxide molecule and a molecule comprising an acidic hydrogen is disclosed. The oxygen atom of the zinc oxide molecule is covalently bound to the acidic hydrogen.

Disclosed herein are methods and compositions for treating, inhibiting, or reducing hair loss, treating, inhibiting, or reducing pigmentation loss, improving or stimulating hair growth, and/or improving or stimulating pigmentation production in a subject with one or more alpha-ketobutyrate compounds and/or one or more glutarate compounds.

Disclosed herein are methods and compositions for treating, inhibiting, or reducing hair loss, treating, inhibiting, or reducing pigmentation loss, improving or stimulating hair growth, and/or improving or stimulating pigmentation production in a subject with one or more alpha-ketobutyrate compounds and/or one or more glutarate compounds.

The present invention relates to a peptide of 14 amino acids having the sequence ID No. 1 or peptide of up to 16 amino acids having a sequence with at least 85%, preferably at least 90%, and preferably at least 95% identity with sequence ID No. 1, or a derivative and/or salt thereof, capable of promoting skin pigmentation and/or innervation in skin dyschromia and/or de-innervation diseases. A pharmaceutical composition comprising such peptide and at least one pharmaceutically acceptable excipient are a further object of the invention.

The present invention relates to a composition for stimulating melanogenesis, comprising Cirsium japonicum extract as an effective ingredient. The composition has no skin irritation and cytotoxicity and is excellent in human stability and very effective in stimulating melanogenesis. Therefore, the composition can be safely used in cosmetic or pharmaceutical composition for preventing, improving or treating vitiligo, white hair or hypopigmentation.

The present invention relates to a composition for stimulating melanogenesis, comprising Cirsium japonicum extract as an effective ingredient. The composition has no skin irritation and cytotoxicity and is excellent in human stability and very effective in stimulating melanogenesis. Therefore, the composition can be safely used in cosmetic or pharmaceutical composition for preventing, improving or treating vitiligo, white hair or hypopigmentation.